Inventiva has extended its cash runway into late Q1 2027 after completing a U.S. public offering in November that...

Hanmi Pharmaceutical will take Aptose Biosciences private, acquiring all remaining shares it does not already own for C$2.41 per...

Valneva reported nine-month 2025 revenues of €127 million, up 9% year over year, alongside a sharp reduction in operating...

BioSyent reported a strong third quarter, with net revenues up 28% to CAD 12.2 million and EBITDA up 27%...

Profusa has completed its reverse recapitalization with NorthView Acquisition Corporation, cut net debt to approximately $14 million as of...

Novartis has rolled forward its mid-term outlook, guiding to a 5–6% constant-currency sales CAGR for 2025–2030 and lifting peak...

Valneva reported nine-month 2025 revenues of €127.0 million, up 8.9% year over year, with product sales rising 6.2% to...

Protext Mobility has issued a broad corporate update: IFRS-audited 2022 and 2023 financials are complete, 2024 filings are underway...

Tempest Therapeutics is acquiring Factor Bioscience’s dual‑targeting CAR‑T programs in an all‑stock deal that will hand an affiliate of...

TG Therapeutics has been ranked number 27 on Deloitte’s Technology Fast 500, recognizing its rapid North American revenue growth...